SCHEMBL20510328

SCHEMBL20510328

COc1ccc(N2CC3CNCC3C2)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.59
CHRNB2 P17787 9/20 0.56
CHRNA4 P43681 9/20 0.56
CHRNB4 P30926 6/20 0.56
CHRNA3 P32297 6/20 0.56
CHRNA7 P36544 4/20 0.56
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
ADRB1 P08588 1/20 0.56
HTR3A P46098 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23732367 1.00 BPTF (0.59) BPTFCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20510515 0.81 ADRB1 (0.59) BPTFCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL21963784 0.81 CHRNB2 (0.66) BPTFCHRNB2CHRNA4CHRNA7LMNA
SCHEMBL23732273 0.81 CHRNB2 (0.66) BPTFCHRNB2CHRNA4CHRNA7LMNA
Hydrochloric Acid SCHEMBL20510780 0.80 ADRB1 (0.58) BPTFCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL23199740 0.80 CHRNB2 (0.68) BPTFCHRNB2CHRNA4CHRNA7LMNA
SCHEMBL27400028 0.79 BPTF (0.66) BPTFCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20510583 0.79 BPTF (0.66) BPTFCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL28956356 0.79 BPTF (0.66) BPTFCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL649807 0.79 CHRNB2 (0.72) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577251-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2026-03-17 US disclosed
US-12338245-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2025-06-24 US disclosed
EP-3600290-B1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE UNIV TEMPLE (US) 2025-06-04 EP disclosed
US-20240300954-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-09-12 US disclosed
US-20240300953-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-09-12 US disclosed
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 US disclosed
US-11807642-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-07 US disclosed
US-10961249-B2 Modulators of the sigma-2 receptor and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-03-30 US disclosed
US-10961249-B2 Modulators of the sigma-2 receptor and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-03-30 US disclosed
US-20200331915-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-10-22 US disclosed
US-20200331915-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-10-22 US disclosed
US-20200039985-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-02-06 US disclosed
US-20200039985-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-02-06 US disclosed
EP-3600290-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2020-02-05 EP disclosed
EP-3600289-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS Temple University - Of The Commonwealth System of Higher Education (US) 2020-02-05 EP disclosed
WO-2018175188-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-09-27 WO disclosed
WO-2018175190-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961249-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, TMEM97, OPRM1 BPTF 3839/4885CHRNB2 48/4885CHRNA4 168/4885
US-20200331915-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS HTR7, HTR6, HTR5A BPTF 2548/4885CHRNB2 167/4885CHRNA4 162/4885
US-20200039985-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 BPTF 3853/4885CHRNB2 35/4885CHRNA4 153/4885
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 BPTF 4706/4885CHRNB2 1327/4885CHRNA4 1249/4885
US-11807642-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents HTR7, HTR6, HTR5A BPTF 2548/4885CHRNB2 167/4885CHRNA4 162/4885
US-20240300953-A1 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS HTR7, HTR6, HTR5A BPTF 2548/4885CHRNB2 167/4885CHRNA4 162/4885
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, TMEM97, OPRM1 BPTF 3839/4885CHRNB2 48/4885CHRNA4 168/4885
US-20240300954-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 BPTF 3853/4885CHRNB2 35/4885CHRNA4 153/4885
US-12338245-B2 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents HTR7, HTR6, HTR5A BPTF 2548/4885CHRNB2 167/4885CHRNA4 162/4885
US-12577251-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, CHRNA6, NR3C2 BPTF 3736/4885CHRNB2 63/4885CHRNA4 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.